Bio Farma Holds Phase 3 Clinical Trial of SOE COVID-19 Vaccine

TEMPO.CO, Padang Pariaman - State-owned pharmaceutical firm Bio Farma held the phase three clinical trial of the SOE COVID-19 Vaccine in four provinces Tuesday, July 12, 2022. The four regions are West Sumatra (Padang Pariaman), West Java (Depok), Central Java (Semarang), and South Sulawesi (Makassar and Jeneponto) with the total target of 4,000 volunteers.

President Director of Bio Farma Honesti Basyir said the final phase of the clinical trial had commenced at the end of 2021. Until the last trial, he claimed that there was no significant side effect or adverse event following immunization (AEFI).

Basyir explained that the homegrown vaccine candidate and the COVID-19 vaccine which has been used massively in the archipelago were different because the SOE vaccine was developed using the Recombinant Protein Subunit method and is halal certified.

“The SOE COVID-19 vaccine is halal and will get a EUA or emergency use authorization from BPOM at the end of July,” he said during a visit to the clinical test center in Padang Pariaman, Tuesday.

After phase three clinical trials and obtaining EUA, Basyir went on, the COVID-19 vaccine was projected to serve as a booster vaccine for adults and a basic vaccine for children.

Bio Farma claimed it was ready to produce 120 million doses per year and even higher if given an assignment by the government.

ANTARA

Click here to get the latest news updates from Tempo in Google News